SlideShare a Scribd company logo
INTRODUCTION TO
DAILY ACTIVITIES OF
CLINICAL PHARMACIST
Dr. Ramesh Bhandari
Asst. Professor
Dept. of Pharmacy Practice
KLE College of Pharmacy, Belagavi
Daily activities of Clinical Pharmacist
 Drug therapy monitoring (medication chart review, clinical
review, pharmacist interventions)
 Ward round participation
 Adverse drug reaction management
 Drug information and poison information
 Medication history
 Patient counselling
 Drug utilisation evaluation and review
 Quality assurance of clinical pharmacy services
Drug Therapy Monitoring
It involves the review of a patient’s medication
regimen to ensure that therapy is appropriate,
safe, efficacious and cost effective.
Also known as drug therapy review or
medication review.
Goals of Drug Therapy Monitoring
Identifying and solving drug related
problems in order to optimize the drug
therapy and patient health outcome.
To ensure all therapeutics objectives
are being achieved.
Significance of Drug Therapy Monitoring
Assess whether desired therapeutic
outcomes are being achieved.
Monitor for drug related problems
Ensure rational and quality use of medicine
Assess patient compliance
Assess the completeness of medication
charts
Components of Drug Therapy Monitoring
A. Medication chart review (MCR) or
Medication order review (MOR) or
Treatment char review (TCR)
B. Clinical review/daily progress review
C. Detection and management of adverse
drug reactions
A. MEDICATION CHART REVIEW
Fundamental responsibility of clinical
pharmacist.
It is a systematic review of a patient’s drug
therapy to ensure that the prescribed
medication is appropriate for the patient.
Involves assessment of all current and recent
medication orders including routine medication
and over the counter drugs and the use of other
system of medicines (unani, ayurvedic, siddha).
Goal of Medication Chart Review
Ensuring that the patient receive
Right drug
Right dose
Right frequency
Right duration
Right dosage form
Steps of Medication Chart Review
1) Collection and interpretation of patient specific
information, including medication history interview
2) Assessment of therapeutic goals
3) Identification of drug related problems
4) Individualising medication regimen
5) Monitoring treatment outcomes
6) Medication chart endorsement
7) Documentation
1. Collection and interpretation of patient specific
information, including medication history interview
First step in setting the therapeutic goal
Need to collect information that will assist them to determine
the appropriateness of drug therapy.
Includes patient’s demographic details such as age, sex and
body weight, social history, presenting complaints, past
medical history, allergy and sensitivity status, current
medications and results of relevant laboratory tests and other
investigations.
Enables the pharmacist to understand the patient disease
condition, indication of drugs and daily clinical progress.
1. Collection and interpretation of patient specific
information, including medication history interview
Sources: Patient, case notes, medication chart,
observational charts, laboratory results and through
discussions with medical and nursing staff.
Further pharmacist can obtain more information which is of
importance to the ongoing medical management of the
patient. (Medication History Interview).
Patient’s medication history should be obtained at the
beginning of the hospital admission in order to provide the
additional useful information to the prescriber.
1. Collection and interpretation of patient specific
information, including medication history interview
Aspects of medication use which may be obtained from
Medication history interview:
History of previous allergies/ADRs
Indication of each medications
Dosing regimen including dose, route, frequency and
duration of therapy
Perceived side effects
Adherence to medication regimen
Use of medication aids
Treatment with other system of medicine (Ayurveda,
siddha, unani)
Use of OTC drugs
Social drug use (tobacco, alcohol, pan masala etc)
1. Collection and interpretation of patient specific
information, including medication history interview
Following interview, data collected should be compared with
the medication charts for any discrepancies (medication
reconciliation) in order to identify drug-related problems.
If any problem exists concerned physician should be
contacted to overcome those drug related problems or to do
any changes in the medication chart.
2. Assessment of Therapeutic goals
To determine the appropriateness of drug therapy it is
essential to understand the therapeutic goals for the
individual patient.
May include one or more of the following:
oCure of the disease
oReduction or elimination of signs and symptoms
oArresting or slowing disease progression
oPreventing disease/symptoms
2. Assessment of Therapeutic goals
Therapeutic goals should based on patient individual
circumstances and may differ from patient to patient based on
their age, co-morbidities and the nature and severity of their
illness.
 Eg: patient with hypertension with diabetes
 40 year old patient – goal should be <130/85 mm of Hg
 >60 years of age – goal should be >150/90 mm of Hg
3. Identification of drug related problems
Reviewing drug therapy should be aimed at identifying and
resolving any drug related problems.
A drug related problem is any event or circumstance
involving drug treatment that interferes or potentially
interferes with the patient achieving an optimum outcome of
medical care.
Charles heplers and Linda strand categorize drug related
problems into 8 categories.
3. Identification of drug related problems
i. Untreated indication
ii. Improper drug selection
iii. Sub-therapeutic dose
iv. Overdosage
v. Adverse drug reactions
vi. Failure to receive drugs
vii. Drug interactions
viii. Drug use without indication
3. Identification of drug related problems
i. Untreated Indications:
Examples:
RA patients using NSAIDs for symptoms relief and may present
symptoms of Gastritis, this situation requires an additional drug
such as H2 blockers ranitidine OR PPI Omeprazole, Pantoprazole to
control gastritis symptoms.
In TB patients INH therapy advised pyridoxine to prevent
peripheral neuropathy caused by INH.
3. Identification of drug related problems
ii. Improper drug selection:
EG: any given drug regimen be considered as wrong for a specific
patient at given time if the dosage form is in appropriate (eg: a 55
year old patient with mild angina receiving nitoglycerin patches to
be applied on daily basis.
Contraindications are present (eg: a pregnant women receiving
Isotretinoin 20mg BD for 2 weeks for acne vulgaris.
3. Identification of drug related problems
iii. Subtherapeutic dose:
Any drug given in lower dose than the recommended.
Eg., A two year old child receiving amoxicillin 40mg
PO(40mg/5ml) for her first episode of otitis media.
3. Identification of drug related problems
iv. Overdosage:
Eg., Any drug given more dose than recommended for
individual patient.
3. Identification of drug related problems
v. Adverse drug reactions:
a) Eg: Ofloxacin induced thrombocytopenic purpura
b) Insulin induced hypoglycemia
c) Penicillin induced hypersensitivity
3. Identification of drug related problems
vi. Failure to receive drugs:
a) Eg., Despite the prescriber order, duty nurse may fail to
administer the drugs.
b) Due to high cost of the drug patient may not purchase the
medication.
c) Due to forgetfulness sometime patient may forget to take the
drugs.
3. Identification of drug related problems
vii. Drug interactions:
a) Eg, Ciprofloxacin and antacids concomitant use can cause failure
of ciprofloxacin therapy.
b) Most of the drugs with grapes juice can cause toxicity of the
drugs.
3. Identification of drug related problems
viii. Drug use without indication:
EG: Nebulization salbutamol 200mcg TID+ Budesonide 100mcg
BID, then patient also Rx with Tab pantoprazole 40mg OD for 10
days, patient has not complained any symptoms of gastritis or PUD
4. Individualising medication regimens
Once DRP relating to the individual drugs on the medication
chart have been resolved, the next step is to consider the
patient’s overall medication regimen.
Important for patients with chronic diseases or those who
are on many drugs on long term basis.
Consider patient data including past medical as well history,
co-morbid conditions, allergic history, and concurrent illness.
Aim should be to simplify the regimen and to adjust the
regimen to maximize long term medication adherence.
4. Individualising medication regimens
Eg:
Switching to slow release formulation of the same drug
Different route of drug administration
Changing time of the doses taken
Switching to a cheaper but effective medications
Combination formulation
5. Monitoring treatment outcome(s)
Key to assess whether the therapeutic goals of drug
treatment achieved or not.
Includes review of the patient’s clinical status, laboratory data
and other markers of drug therapy response.
While evaluating patient’s response to drug therapy, the
pharmacist may need to review information and data from a
number of sources.
5. Monitoring treatment outcome(s)
Eg:
Monitoring antibiotic treatment effects include
examining the patient’s temperature chart, laboratory
data (changes to indices such as white cell count and
inflammatory markers such as ESR and CRP) and case
note entries which describe changes in the signs and
symptoms of the patient’s infection.
Also obtained by patient interview
5. Monitoring treatment outcome(s)
Some therapeutic goals require long term follow-up.
Eg: Response to antidepressants may take up to 4-6 weeks
to become evident.
If therapeutic goals are not achieved within the expected
timeframe, pharmacist should try to identify possible causes
before considering the need for change in therapy.
6. Medication Chart Endorsement
Chart endorsement is one of the primary responsibilities of
the pharmacist in ensuring that medication orders are
unambiguous, legible and complete.
It is essential to avoid medication errors, including those that
might occur at the level of prescribing and or administration
due to incompleteness of the order, lack of adequate
instructions and illegibility.
6. Medication Chart Endorsement
If chart endorsement is required, preferably with immediate
notice to the concerned prescriber, all the necessary details
are endorsed on the chart to avoid any confusion in drug
administration and also to prevent or minimise medication
errors.
6. Medication Chart Endorsement
Following annotations should be considered:
Is the identity of the patient (name and IP/OP number) on
each medication chart?
Is the allergy status of the patient documented?
Is the medication name clear? Abbreviation should be
avoided.
Is the drug prescribed by the generic name?
Is the dose clear? Avoid using abbreviation for units and
fractional doses should be written with zero before decimal
points.
6. Medication Chart Endorsement
Following annotations should be considered:
Is the route of administration specified?
Is the date and time of drug administration clear?
Are any additional drug administrations instructions given
where appropriate?
Is there any over-writing which may lead to confusion?
Is the cancellation of medication order clear and
unambiguous?
Is the prescription signed by doctor?
7. Documentation
Pharmaceutical care provided should be an integral part of
the patient’s medical record.
Documentation of pharmaceutical care provided can be
made either in medication chart or in case notes with a clear
title with pharmacist’s signature.
Documentation of services in the patient’s medical record is
then accessible to all other health care professionals.
Computerisation of relevant information is highly appreciable
which makes easy accessible to health care providers.
B. CLINICAL/DAILY PROGRESS REVIEW
Integral component of medication review
It is the review of the patient’s progress for
the purpose of assessing therapeutic outcome.
Performed on daily basis
Goals of Clinical/Daily Progress Review
Assess the response to drug treatment
Evaluate the safety of the treatment
Assess the progress of the disease and the need for
any change in therapy
Assess the need for monitoring (if any)
Assess the convenience of therapy (to improve
compliance)
Procedure for Clinical/Daily Progress Review
Ideally, clinical review should be done routinely for
all patients.
Usually carried out by attending doctors while
evaluating their patients to monitor the patient
outcome to drug therapy.
While evaluating, the pharmacist may need to review
biochemical, haematological, microbiological and
other investigations as appropriate.
Procedure for Clinical/Daily Progress Review
Clinical Parameters
Signs
Symptoms
Clinical Charts
Temperature Chart
Fluid Balance Chart
Observation Chart
Diabetic Chart
Laboratory Parameters
Biochemistry: Electrolytes, Renal function tests, liver function tests etc
Hematological: WBC, ESR, RBC, Platelets, Hb% etc
Microbiology: Culture tests, antibiotic susceptibility tests
Others: ECG, CT Scan, MRI etc.
Procedure for Clinical/Daily Progress Review
Information obtained must be interpreted and
evaluated with reference to
Clinical features of the existing disease
Need for a laboratory investigation
Aspects related to the drug effects
Past Medication history of the patient
Desired therapeutic outcome(s)
Procedure for Clinical/Daily Progress Review
If therapeutic objectives are not being achieved, the
clinical pharmacist should re-evaluate the
appropriateness of the treatment and discuss any
relevant issues with the clinicians.
C. Detection and management of Adverse Drug
Reaction
One of the most important causes of morbidity and
mortality.
Hence, it is essential that clinical pharmacist should
have knowledge of ADRs including their predictability,
preventability, frequency, severity, predisposing
factors and recognition their causality assessment,
management and prevention.
Definition of ADR
Any response to a drug which is noxious and
unintended, and which occurs at doses normally used
in man for prophylaxis, diagnosis or therapy of
disease, or for the modification of physiological
function. (WHO)
Goal of ADR Management
1) Identification and monitoring of patients susceptible
to ADRs
2) Detection and assessment of ADRs
3) Assisting in the management of ADRs
4) Documentation and prevention of ADRs
1) Identification and monitoring of Patient susceptible to
ADRs
Patients who are most susceptible to develop an ADR
should be identified and monitored on daily basis.
These can be identified during MCR, clinical review or
at the time of medication history interview.
1) Identification and monitoring of Patient susceptible to
ADRs
 Patients who are at high risk of developing an ADR;
 Those with Polypharmacy
 with multiple disease process
Geriatric and paediatric patients
Those with intercurrent diseases (renal/hepatic diseases)
Those treated with highly toxic drugs
Those who are treated with narrow therapeutic index drugs
Those who are treated with drugs that have potential to interacts with
other drugs.
2) Detection and assessment of ADRs
 ADRs may be identified during ward rounds with the medical team and
review of patient’s chart.
 It should considered as part of the broader diagnosis hence, the
differential diagnosis should include the possibility of an ADR.
 Causality relationship between a suspected drug and a reaction, a
temporal or possible association is sufficient for a report to be made.
 The assessment of a causality relationship between a drug and an ADR
is often highly subjective, based on the clinician’s judgment and
experience.
2) Detection and assessment of ADRs
 If an ADR is suspected, the assessment of ADR starts with the
collection of all relevant data pertaining to:
Patient demographics
Medications including non-prescription drugs (OTC)
Comprehensive ADR details (description of the reaction, time of
onset, and duration of the reaction, complication, treatment of the
reaction and outcome of the treatment)
Relevant investigation reports
 By using one or more available causality assessment scales,
correlation of suspected drug with an ADR can be established.
3) Assisting in the management of ADRs
 Based on the severity of an ADR, rapid treatment is necessary. For Eg:,
anaphylactic shock.
 If the culprit drug is obvious, risk-benefit decision needs to be taken
about the need for the drug.
 If several medicines may be due to the non-essential medicines should
be withdrawn.
 If the reaction is likely to be dose related, dose reduction should be
done.
 If the drug is necessary then symptomatic relief may be given while
continuing the essential treatment.
4) Documentation and Prevention of ADRs
 Necessary to prevent re-exposure from the same drug/class
 Attending pharmacist should complete appropriate documentation in the
patient medical record including alert cards or placing sheet in the front
of the patient case notes.
 Essential that medical staff, including the original prescriber are notified
of suspected ADRs
REFERENCE
 G. Parthasarathi, Karin Nyfort Hansen, Milap C Nahata. A textbook of
clinical pharmacy practice Essential concepts and skills. Universities
Press. 2nd edition.
Drug Therapy Monitoring

More Related Content

What's hot

Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
Subhash Yende
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
KRUSHNA ZAMBARE
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
THUSHARA MOHAN
 
Developing therapeutic guidelines
Developing therapeutic guidelines  Developing therapeutic guidelines
Developing therapeutic guidelines
Irene Vadakkan
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
Subhash Yende
 
Drug information final
Drug information finalDrug information final
Drug information final
Sitaram Khadka
 
Drug Information Services
Drug Information ServicesDrug Information Services
Drug Information Services
Dr.Amreen Saba Attariya
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
Urmila Aswar
 
Drug information services
Drug information servicesDrug information services
Drug information services
Dr Manish Pal Singh
 
Quality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy servicesQuality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy services
varshawadnere
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
KRUSHNA ZAMBARE
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substances
Ramesh Ganpisetti
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
Ramesh Ganpisetti
 
Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)
faysalahmed35
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
THUSHARA MOHAN
 
Pharmacy and Therapeutic committee
Pharmacy and Therapeutic committeePharmacy and Therapeutic committee
Pharmacy and Therapeutic committee
APOLLO JAMES
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
Dr. Ramesh Bhandari
 
14ab1 t0011 professional relations and practices of hospital pharmacy
14ab1 t0011  professional relations and practices of hospital pharmacy14ab1 t0011  professional relations and practices of hospital pharmacy
14ab1 t0011 professional relations and practices of hospital pharmacy
Ramesh Ganpisetti
 
Education and Training Program in the Hospital
Education and Training Program in the HospitalEducation and Training Program in the Hospital
Education and Training Program in the Hospital
Subhash Yende
 
clinical pharmacy
clinical pharmacyclinical pharmacy
clinical pharmacy
Sohan Patel
 

What's hot (20)

Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
 
Developing therapeutic guidelines
Developing therapeutic guidelines  Developing therapeutic guidelines
Developing therapeutic guidelines
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Drug information final
Drug information finalDrug information final
Drug information final
 
Drug Information Services
Drug Information ServicesDrug Information Services
Drug Information Services
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Drug information services
Drug information servicesDrug information services
Drug information services
 
Quality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy servicesQuality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy services
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substances
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
 
Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Pharmacy and Therapeutic committee
Pharmacy and Therapeutic committeePharmacy and Therapeutic committee
Pharmacy and Therapeutic committee
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
 
14ab1 t0011 professional relations and practices of hospital pharmacy
14ab1 t0011  professional relations and practices of hospital pharmacy14ab1 t0011  professional relations and practices of hospital pharmacy
14ab1 t0011 professional relations and practices of hospital pharmacy
 
Education and Training Program in the Hospital
Education and Training Program in the HospitalEducation and Training Program in the Hospital
Education and Training Program in the Hospital
 
clinical pharmacy
clinical pharmacyclinical pharmacy
clinical pharmacy
 

Similar to Drug Therapy Monitoring

Session 1- Introduction to Pharmacotherapy.pptx
Session 1- Introduction to Pharmacotherapy.pptxSession 1- Introduction to Pharmacotherapy.pptx
Session 1- Introduction to Pharmacotherapy.pptx
AllyAbdalah
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docx
NbkKarim1
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptx
Anusha Are
 
1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx
yohanneswobie2
 
Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
sunayanamali
 
Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy
ShaistaSumayya
 
CLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptxCLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptx
Bimal Magar
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
Dr. Ramesh Bhandari
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdf
rishi2789
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
raviapr7
 
INTRODUCTION OF CLINICAL PHARMACY
INTRODUCTION OF CLINICAL PHARMACYINTRODUCTION OF CLINICAL PHARMACY
INTRODUCTION OF CLINICAL PHARMACY
Venkata subbareddy Bareddy
 
8 therapeuticdecision-making skills-1
8 therapeuticdecision-making skills-18 therapeuticdecision-making skills-1
8 therapeuticdecision-making skills-1
University of sargodha
 
clinical pharmacy and modern dispensing practice. ...docx
clinical pharmacy and modern dispensing practice. ...docxclinical pharmacy and modern dispensing practice. ...docx
clinical pharmacy and modern dispensing practice. ...docx
Priyayannawar4
 
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
pumulopumulo376
 
pharmaceutical care
pharmaceutical carepharmaceutical care
pharmaceutical care
Dr Arathy R Nath
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy ppt
Nabi Hasan
 
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
MuungoLungwani
 
Clinical pharmacy services
Clinical pharmacy services Clinical pharmacy services
Clinical pharmacy services
SendhilKumar74
 
Pharmacist care services.pptx
Pharmacist care services.pptxPharmacist care services.pptx
Pharmacist care services.pptx
arslan8262
 
Drug_Utilization_Review.ppt
Drug_Utilization_Review.pptDrug_Utilization_Review.ppt
Drug_Utilization_Review.ppt
ashfaq22
 

Similar to Drug Therapy Monitoring (20)

Session 1- Introduction to Pharmacotherapy.pptx
Session 1- Introduction to Pharmacotherapy.pptxSession 1- Introduction to Pharmacotherapy.pptx
Session 1- Introduction to Pharmacotherapy.pptx
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docx
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptx
 
1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx
 
Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
 
Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy
 
CLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptxCLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptx
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdf
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
INTRODUCTION OF CLINICAL PHARMACY
INTRODUCTION OF CLINICAL PHARMACYINTRODUCTION OF CLINICAL PHARMACY
INTRODUCTION OF CLINICAL PHARMACY
 
8 therapeuticdecision-making skills-1
8 therapeuticdecision-making skills-18 therapeuticdecision-making skills-1
8 therapeuticdecision-making skills-1
 
clinical pharmacy and modern dispensing practice. ...docx
clinical pharmacy and modern dispensing practice. ...docxclinical pharmacy and modern dispensing practice. ...docx
clinical pharmacy and modern dispensing practice. ...docx
 
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
pharmaceutical_care_concept.pdf.Basic understanding of the Pharmaceutical car...
 
pharmaceutical care
pharmaceutical carepharmaceutical care
pharmaceutical care
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy ppt
 
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
 
Clinical pharmacy services
Clinical pharmacy services Clinical pharmacy services
Clinical pharmacy services
 
Pharmacist care services.pptx
Pharmacist care services.pptxPharmacist care services.pptx
Pharmacist care services.pptx
 
Drug_Utilization_Review.ppt
Drug_Utilization_Review.pptDrug_Utilization_Review.ppt
Drug_Utilization_Review.ppt
 

More from Dr. Ramesh Bhandari

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
Dr. Ramesh Bhandari
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
Dr. Ramesh Bhandari
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
Dr. Ramesh Bhandari
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
Dr. Ramesh Bhandari
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
Dr. Ramesh Bhandari
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
Dr. Ramesh Bhandari
 
Microbiology
MicrobiologyMicrobiology
Microbiology
Dr. Ramesh Bhandari
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
Dr. Ramesh Bhandari
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
Dr. Ramesh Bhandari
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
Dr. Ramesh Bhandari
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
Dr. Ramesh Bhandari
 
Nutrition
NutritionNutrition
Mother and child health
Mother and child healthMother and child health
Mother and child health
Dr. Ramesh Bhandari
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
Dr. Ramesh Bhandari
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
Dr. Ramesh Bhandari
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
Dr. Ramesh Bhandari
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
Dr. Ramesh Bhandari
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
Dr. Ramesh Bhandari
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Dr. Ramesh Bhandari
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
Dr. Ramesh Bhandari
 

More from Dr. Ramesh Bhandari (20)

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
 
Microbiology
MicrobiologyMicrobiology
Microbiology
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
 
Nutrition
NutritionNutrition
Nutrition
 
Mother and child health
Mother and child healthMother and child health
Mother and child health
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 

Recently uploaded

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 

Recently uploaded (20)

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 

Drug Therapy Monitoring

  • 1. INTRODUCTION TO DAILY ACTIVITIES OF CLINICAL PHARMACIST Dr. Ramesh Bhandari Asst. Professor Dept. of Pharmacy Practice KLE College of Pharmacy, Belagavi
  • 2. Daily activities of Clinical Pharmacist  Drug therapy monitoring (medication chart review, clinical review, pharmacist interventions)  Ward round participation  Adverse drug reaction management  Drug information and poison information  Medication history  Patient counselling  Drug utilisation evaluation and review  Quality assurance of clinical pharmacy services
  • 3. Drug Therapy Monitoring It involves the review of a patient’s medication regimen to ensure that therapy is appropriate, safe, efficacious and cost effective. Also known as drug therapy review or medication review.
  • 4. Goals of Drug Therapy Monitoring Identifying and solving drug related problems in order to optimize the drug therapy and patient health outcome. To ensure all therapeutics objectives are being achieved.
  • 5. Significance of Drug Therapy Monitoring Assess whether desired therapeutic outcomes are being achieved. Monitor for drug related problems Ensure rational and quality use of medicine Assess patient compliance Assess the completeness of medication charts
  • 6. Components of Drug Therapy Monitoring A. Medication chart review (MCR) or Medication order review (MOR) or Treatment char review (TCR) B. Clinical review/daily progress review C. Detection and management of adverse drug reactions
  • 7. A. MEDICATION CHART REVIEW Fundamental responsibility of clinical pharmacist. It is a systematic review of a patient’s drug therapy to ensure that the prescribed medication is appropriate for the patient. Involves assessment of all current and recent medication orders including routine medication and over the counter drugs and the use of other system of medicines (unani, ayurvedic, siddha).
  • 8. Goal of Medication Chart Review Ensuring that the patient receive Right drug Right dose Right frequency Right duration Right dosage form
  • 9. Steps of Medication Chart Review 1) Collection and interpretation of patient specific information, including medication history interview 2) Assessment of therapeutic goals 3) Identification of drug related problems 4) Individualising medication regimen 5) Monitoring treatment outcomes 6) Medication chart endorsement 7) Documentation
  • 10. 1. Collection and interpretation of patient specific information, including medication history interview First step in setting the therapeutic goal Need to collect information that will assist them to determine the appropriateness of drug therapy. Includes patient’s demographic details such as age, sex and body weight, social history, presenting complaints, past medical history, allergy and sensitivity status, current medications and results of relevant laboratory tests and other investigations. Enables the pharmacist to understand the patient disease condition, indication of drugs and daily clinical progress.
  • 11. 1. Collection and interpretation of patient specific information, including medication history interview Sources: Patient, case notes, medication chart, observational charts, laboratory results and through discussions with medical and nursing staff. Further pharmacist can obtain more information which is of importance to the ongoing medical management of the patient. (Medication History Interview). Patient’s medication history should be obtained at the beginning of the hospital admission in order to provide the additional useful information to the prescriber.
  • 12. 1. Collection and interpretation of patient specific information, including medication history interview Aspects of medication use which may be obtained from Medication history interview: History of previous allergies/ADRs Indication of each medications Dosing regimen including dose, route, frequency and duration of therapy Perceived side effects Adherence to medication regimen Use of medication aids Treatment with other system of medicine (Ayurveda, siddha, unani) Use of OTC drugs Social drug use (tobacco, alcohol, pan masala etc)
  • 13. 1. Collection and interpretation of patient specific information, including medication history interview Following interview, data collected should be compared with the medication charts for any discrepancies (medication reconciliation) in order to identify drug-related problems. If any problem exists concerned physician should be contacted to overcome those drug related problems or to do any changes in the medication chart.
  • 14. 2. Assessment of Therapeutic goals To determine the appropriateness of drug therapy it is essential to understand the therapeutic goals for the individual patient. May include one or more of the following: oCure of the disease oReduction or elimination of signs and symptoms oArresting or slowing disease progression oPreventing disease/symptoms
  • 15. 2. Assessment of Therapeutic goals Therapeutic goals should based on patient individual circumstances and may differ from patient to patient based on their age, co-morbidities and the nature and severity of their illness.  Eg: patient with hypertension with diabetes  40 year old patient – goal should be <130/85 mm of Hg  >60 years of age – goal should be >150/90 mm of Hg
  • 16. 3. Identification of drug related problems Reviewing drug therapy should be aimed at identifying and resolving any drug related problems. A drug related problem is any event or circumstance involving drug treatment that interferes or potentially interferes with the patient achieving an optimum outcome of medical care. Charles heplers and Linda strand categorize drug related problems into 8 categories.
  • 17. 3. Identification of drug related problems i. Untreated indication ii. Improper drug selection iii. Sub-therapeutic dose iv. Overdosage v. Adverse drug reactions vi. Failure to receive drugs vii. Drug interactions viii. Drug use without indication
  • 18. 3. Identification of drug related problems i. Untreated Indications: Examples: RA patients using NSAIDs for symptoms relief and may present symptoms of Gastritis, this situation requires an additional drug such as H2 blockers ranitidine OR PPI Omeprazole, Pantoprazole to control gastritis symptoms. In TB patients INH therapy advised pyridoxine to prevent peripheral neuropathy caused by INH.
  • 19. 3. Identification of drug related problems ii. Improper drug selection: EG: any given drug regimen be considered as wrong for a specific patient at given time if the dosage form is in appropriate (eg: a 55 year old patient with mild angina receiving nitoglycerin patches to be applied on daily basis. Contraindications are present (eg: a pregnant women receiving Isotretinoin 20mg BD for 2 weeks for acne vulgaris.
  • 20. 3. Identification of drug related problems iii. Subtherapeutic dose: Any drug given in lower dose than the recommended. Eg., A two year old child receiving amoxicillin 40mg PO(40mg/5ml) for her first episode of otitis media.
  • 21. 3. Identification of drug related problems iv. Overdosage: Eg., Any drug given more dose than recommended for individual patient.
  • 22. 3. Identification of drug related problems v. Adverse drug reactions: a) Eg: Ofloxacin induced thrombocytopenic purpura b) Insulin induced hypoglycemia c) Penicillin induced hypersensitivity
  • 23. 3. Identification of drug related problems vi. Failure to receive drugs: a) Eg., Despite the prescriber order, duty nurse may fail to administer the drugs. b) Due to high cost of the drug patient may not purchase the medication. c) Due to forgetfulness sometime patient may forget to take the drugs.
  • 24. 3. Identification of drug related problems vii. Drug interactions: a) Eg, Ciprofloxacin and antacids concomitant use can cause failure of ciprofloxacin therapy. b) Most of the drugs with grapes juice can cause toxicity of the drugs.
  • 25. 3. Identification of drug related problems viii. Drug use without indication: EG: Nebulization salbutamol 200mcg TID+ Budesonide 100mcg BID, then patient also Rx with Tab pantoprazole 40mg OD for 10 days, patient has not complained any symptoms of gastritis or PUD
  • 26. 4. Individualising medication regimens Once DRP relating to the individual drugs on the medication chart have been resolved, the next step is to consider the patient’s overall medication regimen. Important for patients with chronic diseases or those who are on many drugs on long term basis. Consider patient data including past medical as well history, co-morbid conditions, allergic history, and concurrent illness. Aim should be to simplify the regimen and to adjust the regimen to maximize long term medication adherence.
  • 27. 4. Individualising medication regimens Eg: Switching to slow release formulation of the same drug Different route of drug administration Changing time of the doses taken Switching to a cheaper but effective medications Combination formulation
  • 28. 5. Monitoring treatment outcome(s) Key to assess whether the therapeutic goals of drug treatment achieved or not. Includes review of the patient’s clinical status, laboratory data and other markers of drug therapy response. While evaluating patient’s response to drug therapy, the pharmacist may need to review information and data from a number of sources.
  • 29. 5. Monitoring treatment outcome(s) Eg: Monitoring antibiotic treatment effects include examining the patient’s temperature chart, laboratory data (changes to indices such as white cell count and inflammatory markers such as ESR and CRP) and case note entries which describe changes in the signs and symptoms of the patient’s infection. Also obtained by patient interview
  • 30. 5. Monitoring treatment outcome(s) Some therapeutic goals require long term follow-up. Eg: Response to antidepressants may take up to 4-6 weeks to become evident. If therapeutic goals are not achieved within the expected timeframe, pharmacist should try to identify possible causes before considering the need for change in therapy.
  • 31. 6. Medication Chart Endorsement Chart endorsement is one of the primary responsibilities of the pharmacist in ensuring that medication orders are unambiguous, legible and complete. It is essential to avoid medication errors, including those that might occur at the level of prescribing and or administration due to incompleteness of the order, lack of adequate instructions and illegibility.
  • 32. 6. Medication Chart Endorsement If chart endorsement is required, preferably with immediate notice to the concerned prescriber, all the necessary details are endorsed on the chart to avoid any confusion in drug administration and also to prevent or minimise medication errors.
  • 33. 6. Medication Chart Endorsement Following annotations should be considered: Is the identity of the patient (name and IP/OP number) on each medication chart? Is the allergy status of the patient documented? Is the medication name clear? Abbreviation should be avoided. Is the drug prescribed by the generic name? Is the dose clear? Avoid using abbreviation for units and fractional doses should be written with zero before decimal points.
  • 34. 6. Medication Chart Endorsement Following annotations should be considered: Is the route of administration specified? Is the date and time of drug administration clear? Are any additional drug administrations instructions given where appropriate? Is there any over-writing which may lead to confusion? Is the cancellation of medication order clear and unambiguous? Is the prescription signed by doctor?
  • 35. 7. Documentation Pharmaceutical care provided should be an integral part of the patient’s medical record. Documentation of pharmaceutical care provided can be made either in medication chart or in case notes with a clear title with pharmacist’s signature. Documentation of services in the patient’s medical record is then accessible to all other health care professionals. Computerisation of relevant information is highly appreciable which makes easy accessible to health care providers.
  • 36. B. CLINICAL/DAILY PROGRESS REVIEW Integral component of medication review It is the review of the patient’s progress for the purpose of assessing therapeutic outcome. Performed on daily basis
  • 37. Goals of Clinical/Daily Progress Review Assess the response to drug treatment Evaluate the safety of the treatment Assess the progress of the disease and the need for any change in therapy Assess the need for monitoring (if any) Assess the convenience of therapy (to improve compliance)
  • 38. Procedure for Clinical/Daily Progress Review Ideally, clinical review should be done routinely for all patients. Usually carried out by attending doctors while evaluating their patients to monitor the patient outcome to drug therapy. While evaluating, the pharmacist may need to review biochemical, haematological, microbiological and other investigations as appropriate.
  • 39. Procedure for Clinical/Daily Progress Review Clinical Parameters Signs Symptoms Clinical Charts Temperature Chart Fluid Balance Chart Observation Chart Diabetic Chart Laboratory Parameters Biochemistry: Electrolytes, Renal function tests, liver function tests etc Hematological: WBC, ESR, RBC, Platelets, Hb% etc Microbiology: Culture tests, antibiotic susceptibility tests Others: ECG, CT Scan, MRI etc.
  • 40. Procedure for Clinical/Daily Progress Review Information obtained must be interpreted and evaluated with reference to Clinical features of the existing disease Need for a laboratory investigation Aspects related to the drug effects Past Medication history of the patient Desired therapeutic outcome(s)
  • 41. Procedure for Clinical/Daily Progress Review If therapeutic objectives are not being achieved, the clinical pharmacist should re-evaluate the appropriateness of the treatment and discuss any relevant issues with the clinicians.
  • 42. C. Detection and management of Adverse Drug Reaction One of the most important causes of morbidity and mortality. Hence, it is essential that clinical pharmacist should have knowledge of ADRs including their predictability, preventability, frequency, severity, predisposing factors and recognition their causality assessment, management and prevention.
  • 43. Definition of ADR Any response to a drug which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function. (WHO)
  • 44. Goal of ADR Management 1) Identification and monitoring of patients susceptible to ADRs 2) Detection and assessment of ADRs 3) Assisting in the management of ADRs 4) Documentation and prevention of ADRs
  • 45. 1) Identification and monitoring of Patient susceptible to ADRs Patients who are most susceptible to develop an ADR should be identified and monitored on daily basis. These can be identified during MCR, clinical review or at the time of medication history interview.
  • 46. 1) Identification and monitoring of Patient susceptible to ADRs  Patients who are at high risk of developing an ADR;  Those with Polypharmacy  with multiple disease process Geriatric and paediatric patients Those with intercurrent diseases (renal/hepatic diseases) Those treated with highly toxic drugs Those who are treated with narrow therapeutic index drugs Those who are treated with drugs that have potential to interacts with other drugs.
  • 47. 2) Detection and assessment of ADRs  ADRs may be identified during ward rounds with the medical team and review of patient’s chart.  It should considered as part of the broader diagnosis hence, the differential diagnosis should include the possibility of an ADR.  Causality relationship between a suspected drug and a reaction, a temporal or possible association is sufficient for a report to be made.  The assessment of a causality relationship between a drug and an ADR is often highly subjective, based on the clinician’s judgment and experience.
  • 48. 2) Detection and assessment of ADRs  If an ADR is suspected, the assessment of ADR starts with the collection of all relevant data pertaining to: Patient demographics Medications including non-prescription drugs (OTC) Comprehensive ADR details (description of the reaction, time of onset, and duration of the reaction, complication, treatment of the reaction and outcome of the treatment) Relevant investigation reports  By using one or more available causality assessment scales, correlation of suspected drug with an ADR can be established.
  • 49. 3) Assisting in the management of ADRs  Based on the severity of an ADR, rapid treatment is necessary. For Eg:, anaphylactic shock.  If the culprit drug is obvious, risk-benefit decision needs to be taken about the need for the drug.  If several medicines may be due to the non-essential medicines should be withdrawn.  If the reaction is likely to be dose related, dose reduction should be done.  If the drug is necessary then symptomatic relief may be given while continuing the essential treatment.
  • 50. 4) Documentation and Prevention of ADRs  Necessary to prevent re-exposure from the same drug/class  Attending pharmacist should complete appropriate documentation in the patient medical record including alert cards or placing sheet in the front of the patient case notes.  Essential that medical staff, including the original prescriber are notified of suspected ADRs
  • 51. REFERENCE  G. Parthasarathi, Karin Nyfort Hansen, Milap C Nahata. A textbook of clinical pharmacy practice Essential concepts and skills. Universities Press. 2nd edition.